The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients

AIM: Despite promising preclinical findings regarding clinical utility of farnesyltransferase inhibitors (FTI), such as lonafarnib, success of clinical trials is limited. A multicentre AGO-OVAR-15 phase II trial reported an unfavourable effect of lonafarnib on the outcome of patients with advanced o...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Br J Clin Pharmacol
Päätekijät: Bachmann, Hagen Sjard, Meier, Werner, du Bois, Andreas, Kimmig, Rainer, Kuhlmann, Jan Dominik, Siffert, Winfried, Sehouli, Jalid, Wollschlaeger, Kerstin, Huober, Jens, Hillemanns, Peter, Burges, Alexander, Schmalfeldt, Barbara, Aminossadati, Behnaz, Wimberger, Pauline
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley & Sons, Ltd 2015
Aiheet:
Pharmacogenetics
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4631186/
https://ncbi.nlm.nih.gov/pubmed/26033044
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12688
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia